Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | LYPLAL1 | Q5VWZ2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17731570 | 0.90 | PDE8B (0.43) | PDE8BDYRK1AMETFAAHPDE2A | |
| SCHEMBL17731358 | 0.85 | PDE8B (0.50) | PDE8BMETSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1491129 | 0.78 | PDE8B (0.52) | PDE8BDYRK1AMETFAAHSMN1; SMN2 | |
| SCHEMBL17731447 | 0.78 | MPO (0.40) | PDE8BFAAHPDE2ASMN1; SMN2RAB9A | |
| SCHEMBL17731436 | 0.72 | FAAH (0.42) | FAAHPDE2AALDH1A1HSP90AA1TRAP1 | |
| SCHEMBL12227071 | 0.71 | FAAH (0.58) | FAAHSMN1; SMN2POLBALDH1A1MEN1 | |
| SCHEMBL448730 | 0.70 | PRKCI (0.51) | PDE8BDYRK1ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL17731481 | 0.70 | ALDH1A1 (0.42) | POLBALDH1A1TRAP1 | |
| SCHEMBL28192271 | 0.69 | SMN1; SMN2 (0.58) | FAAHSMN1; SMN2POLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL507189 | 0.69 | PRKCI (0.50) | DYRK1ASMN1; SMN2RAB9AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2019-03-26 | — | — | US | disclosed |
| US-20180282338-A1 | SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2018-10-04 | — | — | US | disclosed |
| EP-3215508-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4]TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073424-A1 | SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239882-B2 | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3A | PDE8B 14/4885DYRK1A 252/4885MET 4148/4885 |
| US-20180282338-A1 | SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3A | PDE8B 14/4885DYRK1A 252/4885MET 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.